• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Breast Cancer, An Issue of Hematology/Oncology Clinics of North America

Breast Cancer, An Issue of Hematology/Oncology Clinics of North America

9780443181856
PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 14 DAYS
544,26 zł
462,62 zł Zniżka 81,64 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 462,62 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD lub Pocztę Polską. Kliknij po więcej szczegółów

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni. Kliknij po więcej szczegółów

Opis
In this issue of Hematology/Oncology Clinics, guest editor Dr. Harold J. Burstein brings his considerable expertise to Breast Cancer. Top experts provide a comprehensive update on multidisciplinary management of early- and late-stage breast cancer, including key topics such as global perspectives on the epidemiology and treatment of breast cancer; breast cancer pathology in the era of genomics; optimizing radiation therapy after breast conserving surgery; and more.
Szczegóły produktu
Elsevier
94004
9780443181856
9780443181856

Opis

Rok wydania
2022
Numer wydania
1
Oprawa
twarda
Liczba stron
240
Wymiary (mm)
152 x 229
Waga (g)
450
  • Disparities in Breast Cancer Outcomes and How to Resolve Them

    Testing for Inherited Susceptibility to Breast Cancer

    Breast Cancer Pathology in the Era of Genomics

    Breast Cancer Pathology in the Era of Genomics

    Role of Ovarian Suppression in Early Premenopausal Breast Cancer

    Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer

    Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

    Biology and Treatment of HER2-Low Breast Cancer

    Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer

    Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer

    The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    Multidisciplinary Management of Brain Metastasis from Breast Cancer

    Systemic Therapy for Hereditary Breast Cancers

    Evidence-Based Guidance for Breast Cancer Survivorship

Komentarze (0)